Probatebeta
Target

TNFRSF17

Tumor necrosis factor receptor superfamily member 17

As of the edition of 20 October 2026, TNFRSF17 (tumor necrosis factor receptor superfamily member 17, UniProt Q02223) has 22 drugs tested at it and 16 companies on the list, 2 on route A and 3 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q02223
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
13
Disease areas
Immune system; Cancer; Blood and lymph; Heart and blood vessels; Nutrition and metabolism; Eye; Skin and connective tissue; Urinary and reproductive
Registered trials of its drugs
281

Drugs at this target

StatusCount
Marketed7
Active8
Stopped4
Status not established3
Total22
DrugStatusFurthest phaseUS protection
Belantamab mafodotinMarketedPhase 3Ends 2032
TeclistamabMarketedPhase 4Ends 2034
ElranatamabMarketedPhase 4Ends 2035
LinvoseltamabMarketedPhase 4Ends 2037
Ciltacabtagene autoleucelMarketedPhase 4Ends 2034
EtentamigActivePhase 3none listed
Idecabtagene vicleucelMarketedPhase 3Ends 2033
JNJ-79635322ActivePhase 3none listed
AlnuctamabActivePhase 3none listed
QLS4131ActivePhase 2none listed
BelantamabMarketedPhase 2none listed
PavurutamabStoppedPhase 1none listed

12 of 22 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A2
Route B3
Engaged8
Undetermined3
Total on the list16
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute B
Bristol Myers SquibbRoute B
RegeneronRoute B

The other 13 companies at TNFRSF17

In the product

16 companies in all; 13 are not named here, and no score is.

See the 16 companies at TNFRSF17, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at TNFRSF17

Other targets in immune system

Companies holding approvals at TNFRSF17